



## Prior Authorization

### Parkinson's Disease – Duopa® (carbidopa and levodopa enteral suspension)

#### Table of Contents

National Formulary Medical Necessity .....	1
Conditions Not Covered.....	2
Background.....	2
References .....	2
Revision History .....	2

#### Product Identifier(s)

**Effective 1/1/23 to 2/27/23:** 108634

**Effective 2/28/23:** 72319

#### INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

#### National Formulary Medical Necessity

**Cigna covers carbidopa-levodopa (Duopa®) enteral suspension as medically necessary when the following criteria are met for FDA Indications or Other Uses with Supportive Evidence:**

Prior Authorization is recommended for prescription benefit coverage of Duopa. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of individuals treated with Duopa as well as the monitoring required for adverse events and long-term efficacy, approval requires Duopa to be prescribed by or in consultation with a physician who specializes in the condition being treated.

#### FDA Indication(s)

- 1. Parkinson's Disease.** Approve for 1 year if the individual meets the following criteria (A, B, C, D, and E):
  - A)** Individual is diagnosed with advanced Parkinson's disease; AND
  - B)** Individual is experiencing "off" episodes such as muscle stiffness, slow movements, or difficulty starting movements; AND

- C) Individual has tried an oral extended-release carbidopa/levodopa therapy and meets one of the following criteria (i or ii):
  - i. Individual had significant intolerance, according to the prescriber; OR
  - ii. Individual had inadequate efficacy, according to the prescriber; AND
- D) Individual has previously tried THREE other treatments for “off” episodes; AND  
Note: Examples of treatment for “off” episodes include entacapone, rasagiline, pramipexole, ropinirole, tolcapone, cabergoline, selegiline, Kynmobi (apomorphine hydrochloride sublingual film), Ongentys (opicapone capsules), or Xadago (safinamide tablets).
- E) Duopa is being prescribed by or in consultation with a neurologist.

## Conditions Not Covered

Carbidopa and levodopa (Duopa®) enteral suspension is considered experimental, investigational or unproven for ANY other use.

## Background

### Overview

Duopa, a combination enteral suspension of carbidopa and levodopa, is indicated for the treatment of motor fluctuations in patients with advanced **Parkinson’s disease**.<sup>1</sup>

### Guidelines

The International Parkinson and Movement Disorder Society published an evidence-based review for treatment for motor symptoms of Parkinson’s disease (2018).<sup>2</sup> The review categorically divides treatment recommendations by Parkinson’s disease characteristics. Duopa is noted to be efficacious and clinically useful for treatment of motor fluctuations, along with likely efficacious and clinically useful for dyskinesia.

## References

1. Duopa® enteral suspension [prescribing information] North Chicago, IL: AbbVie; March 2022.
2. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. *Mov Disord*. 2018;33(8):1248-1266.

## Revision History

Type of Revision	Summary of Changes	Approval Date
Annual Revision	No criteria changes.	09/14/2022

“Cigna Companies” refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc. and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2023 Cigna.